Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis

Next Previous
Trial Profile

The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ESSENCE
  • Sponsors Novo Nordisk

Most Recent Events

  • 15 Dec 2025 According to a Novo Nordisk media release, based on results from this trial the Health Canada has issued marketing authorization with conditions [Notice of Compliance with Conditions (NOC/c)] for Wegovy (semaglutide injection) for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).
  • 28 Oct 2025 According to a Novo Nordisk media release, secondary analysis from this study will be presented in an Oral presentation (0010) and Efficacy response in subgroups will be presented in a poster (4042) on 10 November at the 76th Annual American Association for the Study of Liver Diseases (AASLD) congress, The Liver Meeting 2025, from 7 to 11 November in Washington D.C., U.S.
  • 07 May 2025 According to a Novo Nordisk media release, once-weekly semaglutide 2.4 mg in MASH was submitted for regulatory approval in both the EU and US, and granted priority review in the US.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top